Dr. Sandrock has been a member of the Board of Directors since February 2022 and has served as our President and Chief Executive Officer since March 2022. From February 1998 to December 2021, Dr. Sandrock served in positions of increasing responsibility at Biogen Inc., culminating in his service as Executive Vice President, Research and Development from October 2019 to December 2021. Dr. Sandrock also served in various Chief Medical Officer roles from 2012 to 2020, including as Executive Vice President, Chief Medical Officer for Biogen from October 2015 to January 2020, and served on Biogen’s Executive Committee from June 2013 to December 2021. Dr. Sandrock held other senior executive positions at Biogen during his tenure, including Group Senior Vice President and Chief Medical Officer, Chief Medical Officer and Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock has served on the boards of directors of privately-held biotechnology companies Transition Bio, Inc. since February 2022, Neurimmune, Inc. since February 2022, and Neutargeton Therapeutics since February 2025. Dr. Sandrock served on the boards of directors of publicly-traded biotechnology company Neurocrine Biosciences, Inc. (“Neurocrine”) from September 2015 to May 2020 and privately-held biotechnology companies Praxis Precision Medicines, Inc. from May 2017 to February 2020, Disarm Therapeutics, Inc. from April 2017 to October 2020, Atalanta Therapeutics, Inc. from March 2022 to September 2024, and Verge Genomics Inc. from February 2022 to March 2026. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. We believe Dr. Sandrock’s experience as a senior executive and service on the boards of directors of other life sciences companies qualifies him to serve on the Board of Directors.
What is Alfred Sandrock's net worth?
The estimated net worth of Alfred Sandrock is at least $1.44 million as of April 2nd, 2026. Dr. Sandrock owns 472,549 shares of Voyager Therapeutics stock worth more than $1,441,274 as of July 21st. This net worth approximation does not reflect any other investments that Dr. Sandrock may own. Learn More about Alfred Sandrock's net worth.
How do I contact Alfred Sandrock?
Has Alfred Sandrock been buying or selling shares of Voyager Therapeutics?
Alfred Sandrock has not been actively trading shares of Voyager Therapeutics in the last ninety days. Most recently, Alfred Sandrock sold 11,511 shares of the business's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a transaction totalling $44,547.57. Following the completion of the sale, the chief executive officer now directly owns 472,549 shares of the company's stock, valued at $1,828,764.63. Learn More on Alfred Sandrock's trading history.
Who are Voyager Therapeutics' active insiders?
Are insiders buying or selling shares of Voyager Therapeutics?
In the last year, insiders at the sold shares 9 times. They sold a total of 68,960 shares worth more than $269,884.60. The most recent insider tranaction occured on April, 2nd when CEO Alfred Sandrock sold 11,511 shares worth more than $44,547.57. Insiders at Voyager Therapeutics own 12.7% of the company.
Learn More about insider trades at Voyager Therapeutics. Information on this page was last updated on 4/2/2026.
